NASDAQ · Biotechnology

Angion Biomedica Corp. (ANGN) Stock

$1.00 +0.00% NASDAQ: ANGN Healthcare

Angion Biomedica Corp. operates as a biopharmaceutical enterprise, concentrating its efforts on the identification, advancement, and market introduction of small molecule treatments for severe organ damage and scarring conditions.

Valuation

MetricValue
Price$1.00
Market Cap$30.11M
P/E Ratio-0.42
P/B Ratio-12.67
P/S Ratio0.00
EPS (TTM)$-2.58
52-Week High$20.40
52-Week Low$1.00
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-2000.00%
ROA-177.11%
ROCE-243.08%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity-3.39
Current Ratio2.24

Annual Financials (USD)

Metric20212022202320242025
Revenue$28.0M$2.0M—$0$0
Operating Profit$-39.0M$-30.0M—$-45.0M$-38.0M
Net Profit$-54.0M$-56.0M—$-52.0M$-40.0M
EPS$-1.90$-1.85—$-4.25$-2.58
Op Margin-138.8%-1322.7%———

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$97.0M$53.0M—$28.0M$26.0M
Total Liabilities$15.0M$9.0M—$39.0M$24.0M
Cash$89.0M$50.0M—$18.0M$19.0M
Borrowings$5.0M$4.0M$0$6.0M$5.0M

Latest News

Vallourec to supply pipes for Atapu 2 offshore project in Brazil Offshore Technology · Jul 23, 2026 Micron and Sandisk Are Surging: Can the Rally Last Through 2027? Motley Fool · Jul 23, 2026 1 Dow Jones Stock with Exciting Potential and 2 Facing Headwinds StockStory · Jul 23, 2026 CRIF India Launches Chennai Chapter of 'Credit Goes to HER' to Strengthen Women's Leadership in the Credit Ecosystem PR Newswire · Jul 23, 2026 Net Asset Value(s) Business Wire · Jul 23, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-53.0M$-38.0M$-33.0M$-37.0M$-37.0M
Investing Cash Flow$-1.0M$0$0$0$0
Financing Cash Flow$107.0M$0$46.0M$42.0M$37.0M
Net Cash Flow$54.0M$-38.0M$6.0M$5.0M$0
Free Cash Flow$-53.0M$-38.0M$-33.0M$-37.0M$-37.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.03
EV / EBITDA-0.75
FCF Yield-127.83%
Quick Ratio2.24
Interest Coverage303.06
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About Angion Biomedica Corp.

Angion Biomedica Corp. operates as a biopharmaceutical enterprise, concentrating its efforts on the identification, advancement, and market introduction of small molecule treatments for severe organ damage and scarring conditions. Its primary investigational compound, ANG-3070, is an orally administered tyrosine kinase receptor inhibitor currently being developed to address fibrotic ailments, particularly those impacting the kidneys and lungs. The company's product pipeline also features ANG-3777, a hepatocyte growth factor mimetic engineered to treat acute organ injuries like delayed graft function, in addition to initiatives for ROCK2 inhibitors targeting fibrotic diseases and a CYP11B2 inhibitor program. Established in 1998, Angion Biomedica Corp. maintains its headquarters in Uniondale, New York.

Angion Biomedica Corp. is headquartered in US.

Angion Biomedica Corp. (ANGN) stock trades at $1.00 with a market capitalization of $30.11M. The stock is valued at a price-to-earnings (P/E) ratio of -0.42, price-to-book of -12.67, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.00 and $20.40, and currently trades 95.1% below its 52-week high.

On profitability, Angion Biomedica Corp. generates a return on equity (ROE) of -2000.00%, return on capital employed of -243.08%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.angion.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides